WealthStone’s Exact Sciences EXAS Stock Holding History

WealthStone’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4	Closed	-$472	–	242
2019 Q2	$472	Buy	+4	New	+$403	﹤0.01%	906

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

WealthStone's EXAS Position: Q3 2019 in Review

WealthStone sold out of Exact Sciences (EXAS) in Q3 2019, closing a stake of 4 shares — an estimated $472 sold.

WealthStone first reported a position in EXAS in Q2 2019 and held it in 1 quarter. The position peaked at $472 in Q2 2019. 474 funds tracked by Wall St. Rank hold EXAS as of Q3 2019.

WealthStone reported no remaining Exact Sciences position as of Q3 2019 after selling out during the quarter.
WealthStone sold 4 Exact Sciences shares in Q3 2019, an estimated $472.
WealthStone first reported a position in Exact Sciences in Q2 2019 and held it in 1 quarter.
WealthStone's Exact Sciences position peaked at $472 in Q2 2019.
474 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2019.

Based on WealthStone's 13F filing for Q3 2019, filed 15 Nov 2019.